Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet fut...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and d...
Argonaut Manufacturing Services, a leading contract development manufacturing organization (CDMO) specializing in aseptic drug product manufacturing...
ChemDiv, a global provider of integrated drug discovery solutions, announced the extension of its Chemistry, Manufacturing and Controls (CMC) servi...
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, In...
Reflects Catalent’s unparalleled service and best-in-class capabilities across the pharmaceutical, biotech and consumer health categories Rein...
Lonza to acquire Redberry SAS, an innovative company specializing in rapid microbiology testing solutions Acquisition to include Red One&trade...
Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of a $4 million investm...
SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facili...
Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of virus-ba...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial...
Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commerci...
Dedicated facilities for gelatin and HPMC; 200+ jobs; operations targeted for early 2027; expands ACG's 25-year U.S. presence ACG, the world's most inte...
Through this funding round, the company will initiate the clinical development of its first therapeutic candidate, EVerGel, in 2026, and will enhance its...
© 2025 Biopharma Boardroom. All Rights Reserved.
